Wayne Winegarden, PhD, director of the Center for Medical Economics and Innovation, explains that misaligned incentives are preventing the United States from realizing full benefit from biosimilars.
Patients could save as much as 17% on out-of-pocket costs if they used biosimilars, but many obstacles make that difficult to achieve, noted Wayne Winegarden, PhD, director of the Center for Medical Economics and Innovation at the Pacific Research Institute, a conservative policy analysis group in California.
He believes that legislators have a lot of work to do to pull out the blocks and wedges that prevent full realization of biosimilar savings.
“Since biologic medicines are some of the most expensive drugs that are driving the affordability problem in the United States, biosimilar competition can meaningfully reduce these cost pressures and improve overall affordability,” he said in a recent interview with Managed Healthcare Executive®.
Market dynamics are differnent in Europe, where biosimilar discounts are 20% to 40% lower than in the United States, Winegarden said. That’s a lofty goal to aim for.
The IQVIA Institute for Human Data Science recently developed a scorecard for biosimilar access achievement in the European Union. It showed which countries are ahead in getting biosimilars to patients and why. The country-by-country breakdown rated countries' biosimilar markets on sustainability, the degree to which drug prices have fallen since the introduction of biosimilars, the health of biosimilar competition, and potential for growth. Norway and Sweden and the United Kingdom were among the leading countries for biosimilar adoption, though none of these markets was perfect, according to the analysis. Poland was among the laggers, in part because it takes a year or longer before an approved biosimilar reaches market in that country.
"A lot of my recent research has been looking at biosimilars and specifically trying to quantify the amount of savings that are available, because we haven't had the market develop here the way you have seen biosimilars develop in Europe, nor the same way that you've seen generics developed to become 90% of market here," Winegarden told The Center for Biosimilars® recently.
The biosimilar savings available to Medicare could reach $6.2 billion to $10.5 billion based on Winegarden’s calculation of biosimilars representing 25% to 75% of prescriptions for 9 drug classes for which biosimilars have been approved. “Greater savings can be had if biosimilars reach a higher share and biosimilars are introduced in more drug classes,” he said.
One way to achieve this is to change the incentives that in some cases discourage the use of biosimilars. One thing that tends to happen is that formularies list the more expensive originator biologics as the preferred drug, and so patients must fail on these medications before lower-cost biosimilars can be employed.
He suggested, as a solution, the creation of a formulary tier specifically for lower-cost biosimilars with lower co-pays and coinsurance rates.
Under the current system, providers can actually lose money by prescribing the lower-cost drug, and this is a disincentive that needs to be remedied, Winegarden said. “Removing the disincentives discouraging the development of a healthy biosimilars market is essential for making this happen.”
For more from this interview with Winegarden, visit managedhealthcare.com.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.